A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder
Recent animal studies have shown that pretreatment with centrally active cholecystokinin (CCK) anatagonists blocks the anxiogenic effects of CCK-tetrapeptide (CCK-4). In order to determine whether pretreatment with these antagonists can block the anxiogenic effects of CCK-4 in patients with panic di...
Gespeichert in:
| Veröffentlicht in: | Biological psychiatry (1969) 1992-11, Vol.32 (10), p.903-912 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 912 |
|---|---|
| container_issue | 10 |
| container_start_page | 903 |
| container_title | Biological psychiatry (1969) |
| container_volume | 32 |
| creator | Bradwejn, Jacques Koszycki, Diana Annable, Lawrence du Tertre, Anne Couëtoux Reines, Scott Karkanias, Chris |
| description | Recent animal studies have shown that pretreatment with centrally active cholecystokinin (CCK) anatagonists blocks the anxiogenic effects of CCK-tetrapeptide (CCK-4). In order to determine whether pretreatment with these antagonists can block the anxiogenic effects of CCK-4 in patients with panic disorder, a suitable challenge dose of CCK-4 must be selected. Thus, we conducted a dose range study in which patients with panic disorder (
n = 29) were challenged with CCK-4 (10, 15, 20, or 25 μg) or placebo on two separate occasions, in a balanced incomplete block design. Patients received in random order 10 μg (
n = 12), 15 μg (
n = 11), 20 μg (
n = 12), or 25 μg (
n = 12) of CCK-4 or placebo (
n = 11). CCK-4 induced anxiety and panic responses in a dose-dependent fashion. The incidence of panic attacks following the CCK-4 challenge was 17% (10 μg), 64% (15 μg), 75% (20 μg), and 75% (25 μg). None of the patients panicked with placebo. Moreover, a strong linear relationship between CCK-4 and increases in heart rate and diastolic blood pressure was found. The findings of this study suggest that a dose of 20 μg of CCK-4 (ED
75) might be suitable for efficacy studies of CCK
B antagonists and other potential antipanic drugs in patients with panic disorder. |
| doi_str_mv | 10.1016/0006-3223(92)90179-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73396073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006322392901794</els_id><sourcerecordid>73396073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-ca79fbb57c3bc1bcad5b27aa4e5760dbaa8a459552381a9155e6b8e31361b4f73</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo6zj6DxRyENFDaz473ZeFZfALF7zoOVSS6tlIT6dNugf235txhvXmpYrifaooHkJecvaeM95-YIy1jRRCvu3Fu55x0zfqEdnwzshGKCYek80D8pQ8K-VXHY0Q_IpccdUaafSG7G9oSAWbDNM-TntaljXc0zTQ5Q6pwzs4xpRhpDAF6iGHmI5Q_DpCpjgM6Jdygne7b82CS4YZ5yUGpHGiM0zR0xBLygHzc_JkgLHgi0vfkp-fPv7YfWluv3_-uru5bbzs2qXxYPrBOW28dJ47D0E7YQAUatOy4AA6ULrXWsiOQ8-1xtZ1KLlsuVODkVvy5nx3zun3imWxh1g8jiNMmNZijZR9y2rdEnUGfU6lZBzsnOMB8r3lzJ782pM8e5Jne2H_-rWqrr263F_dAcO_pbPQmr--5FUTjEP16mN5wJTqut50Fbs-Y1hdHCNmW3zEyWOIuUq1IcX___EHd0-XLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73396073</pqid></control><display><type>article</type><title>A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bradwejn, Jacques ; Koszycki, Diana ; Annable, Lawrence ; du Tertre, Anne Couëtoux ; Reines, Scott ; Karkanias, Chris</creator><creatorcontrib>Bradwejn, Jacques ; Koszycki, Diana ; Annable, Lawrence ; du Tertre, Anne Couëtoux ; Reines, Scott ; Karkanias, Chris</creatorcontrib><description>Recent animal studies have shown that pretreatment with centrally active cholecystokinin (CCK) anatagonists blocks the anxiogenic effects of CCK-tetrapeptide (CCK-4). In order to determine whether pretreatment with these antagonists can block the anxiogenic effects of CCK-4 in patients with panic disorder, a suitable challenge dose of CCK-4 must be selected. Thus, we conducted a dose range study in which patients with panic disorder (
n = 29) were challenged with CCK-4 (10, 15, 20, or 25 μg) or placebo on two separate occasions, in a balanced incomplete block design. Patients received in random order 10 μg (
n = 12), 15 μg (
n = 11), 20 μg (
n = 12), or 25 μg (
n = 12) of CCK-4 or placebo (
n = 11). CCK-4 induced anxiety and panic responses in a dose-dependent fashion. The incidence of panic attacks following the CCK-4 challenge was 17% (10 μg), 64% (15 μg), 75% (20 μg), and 75% (25 μg). None of the patients panicked with placebo. Moreover, a strong linear relationship between CCK-4 and increases in heart rate and diastolic blood pressure was found. The findings of this study suggest that a dose of 20 μg of CCK-4 (ED
75) might be suitable for efficacy studies of CCK
B antagonists and other potential antipanic drugs in patients with panic disorder.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/0006-3223(92)90179-4</identifier><identifier>PMID: 1467375</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Anxiety disorders. Neuroses ; Arousal - drug effects ; Biological and medical sciences ; Blood Pressure - drug effects ; Dose-Response Relationship, Drug ; Female ; Heart Rate - drug effects ; Humans ; Injections, Intravenous ; Male ; Medical sciences ; Middle Aged ; Panic - drug effects ; Panic Disorder - diagnosis ; Panic Disorder - psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Tetragastrin</subject><ispartof>Biological psychiatry (1969), 1992-11, Vol.32 (10), p.903-912</ispartof><rights>1992</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-ca79fbb57c3bc1bcad5b27aa4e5760dbaa8a459552381a9155e6b8e31361b4f73</citedby><cites>FETCH-LOGICAL-c386t-ca79fbb57c3bc1bcad5b27aa4e5760dbaa8a459552381a9155e6b8e31361b4f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-3223(92)90179-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4488978$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1467375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bradwejn, Jacques</creatorcontrib><creatorcontrib>Koszycki, Diana</creatorcontrib><creatorcontrib>Annable, Lawrence</creatorcontrib><creatorcontrib>du Tertre, Anne Couëtoux</creatorcontrib><creatorcontrib>Reines, Scott</creatorcontrib><creatorcontrib>Karkanias, Chris</creatorcontrib><title>A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>Recent animal studies have shown that pretreatment with centrally active cholecystokinin (CCK) anatagonists blocks the anxiogenic effects of CCK-tetrapeptide (CCK-4). In order to determine whether pretreatment with these antagonists can block the anxiogenic effects of CCK-4 in patients with panic disorder, a suitable challenge dose of CCK-4 must be selected. Thus, we conducted a dose range study in which patients with panic disorder (
n = 29) were challenged with CCK-4 (10, 15, 20, or 25 μg) or placebo on two separate occasions, in a balanced incomplete block design. Patients received in random order 10 μg (
n = 12), 15 μg (
n = 11), 20 μg (
n = 12), or 25 μg (
n = 12) of CCK-4 or placebo (
n = 11). CCK-4 induced anxiety and panic responses in a dose-dependent fashion. The incidence of panic attacks following the CCK-4 challenge was 17% (10 μg), 64% (15 μg), 75% (20 μg), and 75% (25 μg). None of the patients panicked with placebo. Moreover, a strong linear relationship between CCK-4 and increases in heart rate and diastolic blood pressure was found. The findings of this study suggest that a dose of 20 μg of CCK-4 (ED
75) might be suitable for efficacy studies of CCK
B antagonists and other potential antipanic drugs in patients with panic disorder.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Anxiety disorders. Neuroses</subject><subject>Arousal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Panic - drug effects</subject><subject>Panic Disorder - diagnosis</subject><subject>Panic Disorder - psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Tetragastrin</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo6zj6DxRyENFDaz473ZeFZfALF7zoOVSS6tlIT6dNugf235txhvXmpYrifaooHkJecvaeM95-YIy1jRRCvu3Fu55x0zfqEdnwzshGKCYek80D8pQ8K-VXHY0Q_IpccdUaafSG7G9oSAWbDNM-TntaljXc0zTQ5Q6pwzs4xpRhpDAF6iGHmI5Q_DpCpjgM6Jdygne7b82CS4YZ5yUGpHGiM0zR0xBLygHzc_JkgLHgi0vfkp-fPv7YfWluv3_-uru5bbzs2qXxYPrBOW28dJ47D0E7YQAUatOy4AA6ULrXWsiOQ8-1xtZ1KLlsuVODkVvy5nx3zun3imWxh1g8jiNMmNZijZR9y2rdEnUGfU6lZBzsnOMB8r3lzJ782pM8e5Jne2H_-rWqrr263F_dAcO_pbPQmr--5FUTjEP16mN5wJTqut50Fbs-Y1hdHCNmW3zEyWOIuUq1IcX___EHd0-XLQ</recordid><startdate>19921115</startdate><enddate>19921115</enddate><creator>Bradwejn, Jacques</creator><creator>Koszycki, Diana</creator><creator>Annable, Lawrence</creator><creator>du Tertre, Anne Couëtoux</creator><creator>Reines, Scott</creator><creator>Karkanias, Chris</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19921115</creationdate><title>A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder</title><author>Bradwejn, Jacques ; Koszycki, Diana ; Annable, Lawrence ; du Tertre, Anne Couëtoux ; Reines, Scott ; Karkanias, Chris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-ca79fbb57c3bc1bcad5b27aa4e5760dbaa8a459552381a9155e6b8e31361b4f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Anxiety disorders. Neuroses</topic><topic>Arousal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Panic - drug effects</topic><topic>Panic Disorder - diagnosis</topic><topic>Panic Disorder - psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Tetragastrin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bradwejn, Jacques</creatorcontrib><creatorcontrib>Koszycki, Diana</creatorcontrib><creatorcontrib>Annable, Lawrence</creatorcontrib><creatorcontrib>du Tertre, Anne Couëtoux</creatorcontrib><creatorcontrib>Reines, Scott</creatorcontrib><creatorcontrib>Karkanias, Chris</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bradwejn, Jacques</au><au>Koszycki, Diana</au><au>Annable, Lawrence</au><au>du Tertre, Anne Couëtoux</au><au>Reines, Scott</au><au>Karkanias, Chris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>1992-11-15</date><risdate>1992</risdate><volume>32</volume><issue>10</issue><spage>903</spage><epage>912</epage><pages>903-912</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>Recent animal studies have shown that pretreatment with centrally active cholecystokinin (CCK) anatagonists blocks the anxiogenic effects of CCK-tetrapeptide (CCK-4). In order to determine whether pretreatment with these antagonists can block the anxiogenic effects of CCK-4 in patients with panic disorder, a suitable challenge dose of CCK-4 must be selected. Thus, we conducted a dose range study in which patients with panic disorder (
n = 29) were challenged with CCK-4 (10, 15, 20, or 25 μg) or placebo on two separate occasions, in a balanced incomplete block design. Patients received in random order 10 μg (
n = 12), 15 μg (
n = 11), 20 μg (
n = 12), or 25 μg (
n = 12) of CCK-4 or placebo (
n = 11). CCK-4 induced anxiety and panic responses in a dose-dependent fashion. The incidence of panic attacks following the CCK-4 challenge was 17% (10 μg), 64% (15 μg), 75% (20 μg), and 75% (25 μg). None of the patients panicked with placebo. Moreover, a strong linear relationship between CCK-4 and increases in heart rate and diastolic blood pressure was found. The findings of this study suggest that a dose of 20 μg of CCK-4 (ED
75) might be suitable for efficacy studies of CCK
B antagonists and other potential antipanic drugs in patients with panic disorder.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>1467375</pmid><doi>10.1016/0006-3223(92)90179-4</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-3223 |
| ispartof | Biological psychiatry (1969), 1992-11, Vol.32 (10), p.903-912 |
| issn | 0006-3223 1873-2402 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73396073 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Adult and adolescent clinical studies Anxiety disorders. Neuroses Arousal - drug effects Biological and medical sciences Blood Pressure - drug effects Dose-Response Relationship, Drug Female Heart Rate - drug effects Humans Injections, Intravenous Male Medical sciences Middle Aged Panic - drug effects Panic Disorder - diagnosis Panic Disorder - psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Tetragastrin |
| title | A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A51%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20dose-ranging%20study%20of%20the%20behavioral%20and%20cardiovascular%20effects%20of%20CCK-tetrapeptide%20in%20panic%20disorder&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=Bradwejn,%20Jacques&rft.date=1992-11-15&rft.volume=32&rft.issue=10&rft.spage=903&rft.epage=912&rft.pages=903-912&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/0006-3223(92)90179-4&rft_dat=%3Cproquest_cross%3E73396073%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73396073&rft_id=info:pmid/1467375&rft_els_id=0006322392901794&rfr_iscdi=true |